Spring Bank Pharmaceuticals Inc
Spring Bank Pharmaceuticals — Corporate Update (April 2019)
22 slides from Spring Bank Pharmaceuticals's corporate update, Apr 12, 2019
Slide 1: Conference Call Presentation April 12, 2019
Conference Call Presentation April 12, 2019 SPRING BANK Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements, other than historical facts, regarding: the progress, scope, duration or re
Slide 3: Background
Background 3 Inarigivir ( IRIG ) is being developed as an oral immunomodulatory backbone agent for combination strategies to achieve HBV Functional Cure Achievement of “Functional Cure” in HBV requires: Loss of HBsAg or sustained suppression of HBV DNA off all treatment after a finite duration of th
Slide 4: Inarigivir Acts Through Modulation of the Innate Immune System Involving RIG-I
4 Inarigivir Acts Through Modulation of the Innate Immune System Involving RIG-I Novel mechanism of action Actively transported into hepatocytes via OATP-1 and OAT-1 with 30:1 liver to plasma ratio Binds to RIG-I and causes induction of IFN signaling Demonstrated activation of immune system in HCV p
Slide 5: Healthy Volunteers Trial Design
Healthy Volunteers Trial Design 5 Inarigivir 400 mg /Daily 12 days: 14 healthy volunteers Day 1 Day 12 11 Days 400 mg Samples Cytokines in sera (IFN-a, IP-10, TNF-a, IFN-g, IL-6, IL-12p70) PBMC for flow cytometry analysis (T, NK, myeloid cells activation) PBMC for Nanostring analysis 0 4h 12h 0 2h 2
Slide 6: Evidence of Immune Activation without Systemic Cytokine Toxicity
Evidence of Immune Activation without Systemic Cytokine Toxicity 6 Serum cytokines levels of IFN-a, IFN-g, TNF-a, IL-6 and IL-12p70 were undetectable while IP-10 levels declined after inarigivir treatment As early as 2h post treatment, phenotypic analysis showed uniform up-regulation of activation m
Slide 7: Inarigivir Cross-Resistance Studies
Inarigivir Cross-Resistance Studies 7 Inarigivir effective against all known NUC resistant variants Inarigivir effective against pre-core mutation stop codon G1896A Inarigivir effective against all known capsid resistance variants Inarigivir will cover pre-existing NUC / CpAM variants and prevent em
Slide 8: ACHIEVE Phase 2 Dose Escalation Study
PRIMARY ENDPOINT SECONDARY ENDPOINT Safety and antiviral activity at 12 weeks PK, change in serum HBV DNA, HBsAg, HBV RNA and HBeAg from baseline to weeks 6, 12, 14, 16, and 24 Up to 80 non-cirrhotic HBV subjects, randomized 4:1 between inarigivir and placebo Inarigivir - 200 mg Placebo Inarigivir -
Slide 9: Mean Baseline Demographics by IRIG Dosing Cohort and HBeAg Status
Mean Baseline Demographics by IRIG Dosing Cohort and HBeAg Status 9
Slide 10: Primary Endpoint: Mean Change from Baseline in HBV DNA
Primary Endpoint: Mean Change from Baseline in HBV DNA at Week 12 in Placebo (PL) and IRIG Cohorts 10 IRIG Dose (mg) Log10 -0.02 -0.58 -0.73 -0.95 -1.54
Slide 11: HBeAg-Positive Patients: Change from Baseline in HBV DNA
HBeAg-Positive Patients: Change from Baseline in HBV DNA at Week 12 and Week 24 11
Slide 12: HBeAg-Negative Patients: Change from Baseline in HBV DNA
12 HBeAg-Negative Patients: Change from Baseline in HBV DNA at Week 12 and Week 24 18 of 22 (82%) patients undetectable at week 24
Slide 13: Secondary Endpoint: Mean Change from Baseline in HBV RNA
Secondary Endpoint: Mean Change from Baseline in HBV RNA at Week 12 in Placebo (PL) and IRIG Cohorts 13 Log10 -0.1 -1.0 -0.8 -0.81 -1.14 PL 25mg 50mg 100mg 200mg IRIG DOSE
Slide 14: HBeAg-Positive Patients: Change from Baseline in HBV RNA
HBeAg-Positive Patients: Change from Baseline in HBV RNA at Week 12 and Week 24 14
Slide 15: HBeAg-Negative Patients: Change from Baseline in HBV RNA
HBeAg-Negative Patients: Change from Baseline in HBV RNA at Week 12 and Week 24 15 All IRIG patients at 50, 100 and 200mg became undetectable at week 12
Slide 16: Baseline HBsAg Cutoff of 4log10 Predictor of Response
Baseline HBsAg Cutoff of 4log10 Predictor of HBV DNA and HBV RNA Response to IRIG at Week 12 16
Slide 17: Positive Predictors of Response for IRIG HBV DNA and HBV RNA
Positive Predictors of Response for IRIG 17 HBV DNA and HBV RNA Baseline HBsAg < 4log10 Baseline IP-10 > 310ng/L Reduction in IP-10 > 110ng/L between baseline and week 12 HBsAg Genotype B > C Good responses genotype A / D but numbers small
Slide 18: Secondary Endpoint: Predefined Responders with HBsAg Reduction
Secondary Endpoint: Predefined Responders with HBsAg Reduction of > 0.5log10 18
Slide 19: Quantitative HBsAg Responder Patients
Quantitative HBsAg Responder Patients > 0.5log10 Reduction at Week 12 or Week 24 from Baseline 19
Slide 20: HBsAg Response (>0.5log10) by Genotype
HBsAg Response (> 0.5log10) by Genotype 20
Slide 21: Preliminary Safety Analysis
Preliminary Safety Analysis 21 Most common mild / moderate TEAE’s all groups Headache / dizziness 13; fatigue 9; abd pain/GI upset 10; Flu / flu like symptoms 5URTI 10; ALT / AST elevation: 8 1 Grade 3 transient hypertriglyceridemia not sustained on retesting 1 SAE of hospitalization for knee pain,
Slide 22: Conclusion
Conclusion 22 IRIG demonstrated dose dependent responses for HBV DNA and HBV RNA Baseline HBsAg major predictor of HBV DNA and HBV RNA response HBsAg response seen in 26% of patients at either 12 or 24 weeks Responders seen at every dose and may indicate response more dependent on host immunity More
Spring Bank Pharmaceuticals — Corporate Update (April 2019) on 6ix